<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1150" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1150/" /><meta name="ncbi_pagename" content="Hypophosphatasia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hypophosphatasia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hypophosphatasia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/02/04" /><meta name="citation_author" content="Etienne Mornet" /><meta name="citation_author" content="Mark E Nunes" /><meta name="citation_pmid" content="20301329" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1150/" /><meta name="citation_keywords" content="Alkaline phosphatase, tissue-nonspecific isozyme" /><meta name="citation_keywords" content="ALPL" /><meta name="citation_keywords" content="Hypophosphatasia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hypophosphatasia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Etienne Mornet" /><meta name="DC.Contributor" content="Mark E Nunes" /><meta name="DC.Date" content="2016/02/04" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1150/" /><meta name="description" content="Hypophosphatasia is characterized by defective mineralization of bone and/or teeth in the presence of low activity of serum and bone alkaline phosphatase. Clinical features range from stillbirth without mineralized bone at the severe end to pathologic fractures of the lower extremities in later adulthood at the mild end. Although the disease spectrum is a continuum, six clinical forms are usually recognized based on age at diagnosis and severity of features:" /><meta name="og:title" content="Hypophosphatasia" /><meta name="og:type" content="book" /><meta name="og:description" content="Hypophosphatasia is characterized by defective mineralization of bone and/or teeth in the presence of low activity of serum and bone alkaline phosphatase. Clinical features range from stillbirth without mineralized bone at the severe end to pathologic fractures of the lower extremities in later adulthood at the mild end. Although the disease spectrum is a continuum, six clinical forms are usually recognized based on age at diagnosis and severity of features:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1150/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hops/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1150/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C9E8DE040B1C10000000003030116.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1150_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1150_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hypo-mcc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/image/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1150_"><span class="title" itemprop="name">Hypophosphatasia</span></h1><p class="contrib-group"><span itemprop="author">Etienne Mornet</span>, PhD and <span itemprop="author">Mark E Nunes</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1150_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1150_ai__"><div class="contrib half_rhythm"><span itemprop="author">Etienne Mornet</span>, PhD<div class="affiliation small">Unit&#x000e9; de G&#x000e9;n&#x000e9;tique Constitutionnelle<br />Centre Hospitalier de Versailles<br />Versailles, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.selliasrev-hc@tenrome" class="oemail">rf.selliasrev-hc@tenrome</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Mark E Nunes</span>, MD<div class="affiliation small">Division Chief, Medical Genetics<br />San Diego Medical Center<br />Kaiser Permanente<br />San Diego, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.pk@senun.e.kram" class="oemail">gro.pk@senun.e.kram</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">November 20, 2007</span>; Last Update: <span itemprop="dateModified">February 4, 2016</span>.</p><p><em>Estimated reading time: 31 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hops.Summary" itemprop="description"><h2 id="_hops_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hypophosphatasia is characterized by defective mineralization of bone and/or teeth in the presence of low activity of serum and bone alkaline phosphatase. Clinical features range from stillbirth without mineralized bone at the severe end to pathologic fractures of the lower extremities in later adulthood at the mild end. Although the disease spectrum is a continuum, six clinical forms are usually recognized based on age at diagnosis and severity of features:</p><ul><li class="half_rhythm"><div>Perinatal (severe) hypophosphatasia characterized by respiratory insufficiency and hypercalcemia</div></li><li class="half_rhythm"><div>Perinatal (benign) hypophosphatasia with prenatal skeletal manifestations that slowly resolve into one of the milder forms</div></li><li class="half_rhythm"><div>Infantile hypophosphatasia with onset between birth and age six months of rickets without elevated serum alkaline phosphatase activity</div></li><li class="half_rhythm"><div>Childhood (juvenile) hypophosphatasia that ranges from low bone mineral density for age with unexplained fractures to rickets, and premature loss of primary teeth with intact roots</div></li><li class="half_rhythm"><div>Adult hypophosphatasia characterized by stress fractures and pseudofractures of the lower extremities in middle age, sometimes associated with early loss of adult dentition</div></li><li class="half_rhythm"><div>Odontohypophosphatasia characterized by premature exfoliation of primary teeth and/or severe dental caries without skeletal manifestations</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Although formal diagnostic criteria are not established, all forms of hypophosphatasia (except pseudohypophosphatasia) share in common reduced activity of unfractionated serum alkaline phosphatase (ALP) and presence of either one or two pathogenic variants in <i>ALPL</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding alkaline phosphatase, tissue-nonspecific isozyme (TNSALP).</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations</i>: Perinatal (severe) type: limited experience with enzyme replacement therapy (ERT); expectant management and family support. Infantile and early childhood (juvenile) types: enzyme replacement therapy (asfotase alfa), respiratory support, treatment of hypercalcemia/hypercalciuria, treatment of seizures with vitamin B<sub>6</sub>, routine treatment of craniosynostosis. All other types: routine dental care starting at age one year; nonsteroidal anti-inflammatory drugs (NSAID) for osteoarthritis, bone pain, and osteomalacia; internal fixation for pseudofractures and stress fractures.</p><p><i>Surveillance</i>: Dental visits twice yearly starting at age one year; monitoring children with infantile type for increased intracranial pressure secondary to craniosynostosis.</p><p><i>Agents/circumstances to avoid</i>: Bisphosphonates, excess vitamin D.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Perinatal and most infantile cases of hypophosphatasia are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. The milder forms, especially adult and odontohypophosphatasia, may be inherited in an autosomal recessive or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner depending on the effect that the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has on TNSALP activity.</p><ul><li class="half_rhythm"><div><i>Autosomal recessive hypophosphatasia.</i> Heterozygotes (carriers) either are asymptomatic (manifesting biochemical but not clinical abnormality) or may manifest milder symptoms, depending on the variant. Although <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have been reported, in most instances each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an "asymptomatic" <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div><i>Autosomal dominant hypophosphatasia</i>. To date, all probands have inherited a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a parent; <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variants have not been reported. Each child of an individual with the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of hypophosphatasia has a 50% chance of inheriting the pathogenic variant.</div></li></ul><p>Prenatal diagnosis for pregnancies at increased risk is possible if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Recurrence of perinatal and infantile hypophosphatasia may reliably be identified by prenatal ultrasound examination.</p></div></div><div id="hops.Diagnosis"><h2 id="_hops_Diagnosis_">Diagnosis</h2><div id="hops.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hypophosphatasia <b>should be suspected</b> in individuals with:</p><ul><li class="half_rhythm"><div>Defective mineralization of bone and/or teeth;</div></li><li class="half_rhythm"><div>Premature loss of teeth with intact roots;</div></li><li class="half_rhythm"><div>Reduced serum alkaline phosphatase (ALP) activity.</div></li></ul><p>At least six clinical forms are currently recognized based on age at diagnosis and severity of features (see <a class="figpopup" href="/books/NBK1150/table/hops.T.clinical_features_of_hypophosphat/?report=objectonly" target="object" rid-figpopup="fighopsTclinicalfeaturesofhypophosphat" rid-ob="figobhopsTclinicalfeaturesofhypophosphat">Table 1</a>). <b>Clinical features</b> include the following:</p><ul><li class="half_rhythm"><div><b>Prenatal long-bone bowing</b> with osteochondral spurs and pretibial dimpling</div></li><li class="half_rhythm"><div><b>Infantile rickets without elevated serum alkaline phosphatase activity.</b> Features can include growth failure, craniotabes, craniosynostosis, blue sclerae, costochondral enlargement ("rachitic rosary"), scoliosis, thickening of wrists and ankles, bowing of long bones, lax ligaments, and hypotonia.</div></li><li class="half_rhythm"><div><b>Hypercalcemia and hypercalciuria</b> particularly during the first year of life</div></li><li class="half_rhythm"><div><b>Pathologic fractures</b> and bone pain. Growing children may have a predilection to metaphyseal fractures; however, epiphyseal and diaphyseal fractures are also seen. In adults, metatarsal stress fractures and femoral pseudofractures prevail.</div></li><li class="half_rhythm"><div><b>Premature loss of deciduous teeth</b> beginning with the incisors. Unusually and characteristically, the dental root remains attached to the lost tooth. Dental caries and early loss or extraction of adult teeth is also seen.</div></li><li class="half_rhythm"><div><b>Family history</b> of any of the forms of hypophosphatasia consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance with <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a></div></li></ul><p>The <b>radiographic signs</b> of hypophosphatasia vary with age and type, and may be quite distinctive. Perinatal lethal hypophosphatasia is radiographically distinct. In milder cases, the combination of clinical, laboratory, and radiographic findings are required for diagnosis because the radiographic signs are not pathognomonic.</p><ul><li class="half_rhythm"><div><b>Osteopenia, osteoporosis, or low bone mineral content for age</b> detected by dual-energy x-ray absorptiometry (DEXA). Bone mineral content increases with age, and there may be improvement during adolescence with recurrence in middle age.</div></li><li class="half_rhythm"><div><b>Infantile rickets.</b> Findings include undermineralized bones, widened-appearing sutures, brachycephaly, flail chest, rachitic costochondral rib changes (see <a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1A</a>), flared metaphyses (resulting in enlarged wrists, knees, and ankles), poorly ossified epiphyses, and bowed legs.</div></li><li class="half_rhythm"><div><b>Alveolar bone loss</b> resulting in premature loss of deciduous teeth. This most typically involves the anterior mandible, with the central incisors lost first. However, any tooth may be affected (see <a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1B</a>).</div></li><li class="half_rhythm"><div><b>Focal bony defects of the metaphyses</b> resembling radiolucent "tongues" (see <a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1C</a>). This feature is fairly specific for childhood (juvenile) hypophosphatasia.</div></li><li class="half_rhythm"><div><b>Metatarsal stress fractures</b> in childhood (juvenile) and adult hypophosphatasia</div></li><li class="half_rhythm"><div><b>Osteomalacia with lateral pseudofractures (Looser zones)</b> in adult hypophosphatasia (see <a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1D</a>)</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighopsF1" co-legend-rid="figlgndhopsF1"><a href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fighopsF1" rid-ob="figobhopsF1"><img class="small-thumb" src="/books/NBK1150/bin/hops-Image001.gif" src-large="/books/NBK1150/bin/hops-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndhopsF1"><h4 id="hops.F1"><a href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-ob="figobhopsF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Radiographic signs of hypophosphatasia A. Rachitic rib changes, flail chest, and metaphyseal dysplasia (proximal humerus) in infantile hypophosphatasia</p></div></div><div id="hops.T.clinical_features_of_hypophosphat" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Clinical Features of Hypophosphatasia by Type</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1150/table/hops.T.clinical_features_of_hypophosphat/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hops.T.clinical_features_of_hypophosphat_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Type</th><th id="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inheritance</th><th id="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardinal Features</th><th id="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dental Features</th><th id="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Diagnosis</th></tr></thead><tbody><tr><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Perinatal (severe)</b></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomineralization, osteochondral spurs</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x000b1;&#x000a0;<sup>1</sup></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Radiographs, prenatal ultrasound examination</td></tr><tr><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Perinatal (benign)</b></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR or AD</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Long-bone bowing, benign postnatal course</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x000b1;</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prenatal ultrasound examination, clinical course</td></tr><tr><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Infantile&#x000a0;<sup>2</sup></b></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mostly AR</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Craniosynostosis, Hypomineralization, rachitic ribs, hypercalciuria</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Premature loss, deciduous teeth</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical course, radiographs, laboratory findings</td></tr><tr><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Childhood</b><br /><b>(juvenile)</b></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR or AD</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature, skeletal deformity, bone pain/fractures</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Premature loss, deciduous teeth (incisors)</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical course, radiographs, laboratory findings</td></tr><tr><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Adult&#x000a0;<sup>3</sup></b></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR or AD</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stress fractures: metatarsal, tibia; chondrocalcinosis</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x000b1;</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical course, radiographs, laboratory findings</td></tr><tr><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Odontohypo-</b><br /><b>phosphatasia</b></td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR or AD</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alveolar bone loss</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exfoliation (incisors), dental caries</td><td headers="hd_h_hops.T.clinical_features_of_hypophosphat_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical course, dental panorex, laboratory findings</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a></p></div></dd><dt>1. </dt><dd><div id="hops.TF.1.1"><p class="no_margin">In the past individuals with severe phenotypes have typically died before teeth erupted and could be lost. In the new &#x0201c;treated perinatal (severe) and infantile&#x0201d; category, the dental features are not precisely known but emerging data suggests the possibility of such features.</p></div></dd><dt>2. </dt><dd><div id="hops.TF.1.2"><p class="no_margin">Rare reported cases of infantile hypophosphatasia that have normal serum alkaline phosphatase activity (in vitro) have been designated "pseudohypophosphatasia." The biochemical and molecular basis of pseudohypophosphasia remains unclear.</p></div></dd><dt>3. </dt><dd><div id="hops.TF.1.3"><p class="no_margin">Persons with adult hypophosphatasia may give a history of features typically reported in childhood (juvenile), infantile, and even prenatal hypophosphatasia.</p></div></dd></dl></div></div></div></div><div id="hops.Laboratory_Testing"><h3>Laboratory Testing</h3><p><b>Total serum alkaline phosphatase (ALP) activity: low.</b> In all the types of hypophosphatasia, serum ALP activity is low.</p><ul><li class="half_rhythm"><div>Laboratories both within and across countries use different methods and thus have very different reference ranges; <b>the gender- and age-specific reference range determined by each reference laboratory should be used.</b> See <a href="/books/NBK1150/bin/hops-Table2.pdf">Table 2</a> (pdf) for typical lowest normal reference values.</div></li><li class="half_rhythm"><div>Transient increases in serum ALP activity in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals invariably occur during pregnancy. Small increases in serum ALP activity may be seen with liver disease and acute fracture or surgery. Thus, serial measurement of serum ALP activity may be necessary when the diagnosis is suspected in toddlers with unexplained fractures.</div></li><li class="half_rhythm"><div>Quantitation of the activity of the bone isoform of ALP in serum is generally unnecessary; however, in the setting of liver disease, the serum activity of ALP may be "falsely" normal. The bone isoform is heat labile; the liver isoform heat stable.</div></li></ul><p><b>Urine concentration of phosphoethanolamine (PEA): elevated</b></p><ul><li class="half_rhythm"><div class="half_rhythm">This is the most commonly obtained secondary screen for hypophosphatasia. It may be obtained as part of a urine amino acid chromatogram.</div></li><li class="half_rhythm"><div class="half_rhythm">An elevated urine concentration of PEA supports the diagnosis of hypophosphatasia; however, the concentration in urine may be elevated with other metabolic bone disease and may be normal in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div><div class="half_rhythm">Note: Finding an elevated urine concentration of proline adds specificity in interpretation of test results.</div></li><li class="half_rhythm"><div class="half_rhythm">Asymptomatic heterozygotes may have reduced serum ALP activity and increased urine PEA concentration.</div></li></ul><p><b>Serum concentration of pyridoxal 5'-phosphate (PLP): elevated</b></p><ul><li class="half_rhythm"><div>This biologically active metabolite of vitamin B<sub>6</sub> may be the most sensitive indicator of hypophosphatasia [<a class="bk_pop" href="#hops.REF.cole.1986.992">Cole et al 1986</a>].</div></li><li class="half_rhythm"><div>Many reference laboratories measuring vitamin B<sub>6</sub> either (1) measure PLP and report as &#x0201c;vitamin B<sub>6</sub>&#x0201d; or (2) report the PLP level; thus, ordering &#x0201c;vitamin B<sub>6</sub>&#x0201d; may suffice if PLP is not an option.</div></li><li class="half_rhythm"><div>Use of vitamin supplements within a week of assaying serum concentration of PLP may lead to false positive results.</div></li></ul><p><b>Serum concentration of calcium, ionized calcium, and inorganic phosphate: normal</b></p><ul><li class="half_rhythm"><div>Normal levels distinguish hypophosphatasia from other forms of rickets.</div></li><li class="half_rhythm"><div>Hypercalciuria may be present with or without elevated serum concentration of calcium.</div></li><li class="half_rhythm"><div>Although inorganic phosphate concentration in serum or urine is most typically normal, it may be elevated and thus is too variable to be used in diagnosis.</div></li></ul><p><b>Serum concentration of vitamin D (25-hydroxy and 1,25-dihydroxy) and parathyroid hormone (nPTH): normal</b></p><p><b>Urine inorganic pyrophosphate (PPi): elevated</b></p><ul><li class="half_rhythm"><div>This is a sensitive marker in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and asymptomatic heterozygotes.</div></li></ul></div><div id="hops.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>Except in prenatal context where genetic diagnosis is essential, hypophosphatasia can be often diagnosed by routine clinical, biochemical, and radiographic means. The diagnosis is confirmed in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants or a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ALPL</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1150/table/hops.T.clinical_features_of_hypophosphat/?report=objectonly" target="object" rid-figpopup="fighopsTclinicalfeaturesofhypophosphat" rid-ob="figobhopsTclinicalfeaturesofhypophosphat">Table 1</a>).</p><p>Molecular testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ALPL</i> is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ALPL</i> and other genes of interest (see <a href="#hops.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>ALPL</i>) fails to confirm a diagnosis in an individual with features of hypophosphatasia. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="hops.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hypophosphatasia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1150/table/hops.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hops.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ALPL</i></td><td headers="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02248;95%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_hops.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hops.TF.3.1"><p class="no_margin">See <a href="/books/NBK1150/#hops.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hops.TF.3.2"><p class="no_margin">See <a href="#hops.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hops.TF.3.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hops.TF.3.4"><p class="no_margin">In individuals with severe (perinatal and infantile) hypophosphatasia, two <i>ALPL</i> pathogenic variants are identified in approximately 95% of individuals of European ancestry. In other forms, one or two <i>ALPL</i> pathogenic variants are detected, depending on the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>.</p></div></dd><dt>5. </dt><dd><div id="hops.TF.3.5"><p class="no_margin">In more moderate forms in which one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is believed sufficient to cause disease, the rate of detection of pathogenic variants is more difficult to estimate. Overall, about 50% have two <i>ALPL</i> pathogenic variants (compound <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> or homozygote); about 40%-45% only one identified pathogenic variant. The milder the disease, the higher the proportion in which only one <i>ALPL</i> pathogenic variant is detected.</p></div></dd><dt>6. </dt><dd><div id="hops.TF.3.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="hops.TF.3.7"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available. A few deletions have been reported [<a class="bk_pop" href="#hops.REF.spentchian.2006.252">Spentchian et al 2006</a>, <a class="bk_pop" href="#hops.REF.mornet.2015">Mornet 2015</a>] (see <a href="http://www.sesep.uvsq.fr/03_hypo_mutations.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www<wbr style="display:inline-block"></wbr>​.sesep.uvsq.fr</a>).</p></div></dd></dl></div></div></div></div></div><div id="hops.Clinical_Characteristics"><h2 id="_hops_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hops.Clinical_Description"><h3>Clinical Description</h3><p>The clinical features of hypophosphatasia represent a spectrum ranging from stillbirth without mineralized bone to pathologic fractures of the lower extremities in later adulthood [<a class="bk_pop" href="#hops.REF.whyte.1994.439">Whyte 1994</a>].</p><p><b>General features of hypophosphatasia.</b> Clinical features of rickets or osteomalacia, of varying severity, are seen at all ages. Within families, several forms may be seen in family members with <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> variants. Stillbirth without mineralized bone defines the most severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. &#x0201c;Paradoxical&#x0201d; rickets, in which the serum alkaline phosphatase is not elevated (as it would be in nutritional or renal rickets) is typical. Pathologic stress fractures of the lower extremities (femoral head, tibia, and metatarsals) in older adults define the mild end. All cases are characterized by:</p><ul><li class="half_rhythm"><div>Defective mineralization of bone and/or teeth;</div></li><li class="half_rhythm"><div>Reduced serum alkaline phosphatase (ALP) activity.</div></li></ul><p><b>Histologic evaluation</b></p><ul><li class="half_rhythm"><div>Bone histology reveals rachitic abnormalities of the growth plate. Histochemical testing of osteoclasts reveals lack of membrane-associated ALP activity. Osteoclasts and osteoblasts otherwise appear normal.</div></li><li class="half_rhythm"><div>Tooth histology reveals a decrease in cementum, which varies with the severity of the disease.</div></li></ul><p><b>Specific phenotypes</b> include the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Perinatal (severe) hypophosphatasia</b> is typically identified by prenatal ultrasound examination. Pregnancies may end in stillbirth. Small thoracic cavity and short, bowed limbs are seen in both liveborn and stillborn infants. A flail chest may be present (<a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1A</a>). Infants with perinatal hypophosphatasia may experience pulmonary insufficiency; restrictive lung disease is the most frequent cause of death. Hypercalcemia is common and may be associated with apnea or seizures.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Perinatal (benign) hypophosphatasia</b> is typically identified by prenatal ultrasound examination showing short and bowed long bones but normal or slightly decreased mineralization. Postnatally, skeletal manifestations slowly resolve with a less severe hypophosphatasia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#hops.REF.pauli.1999.434">Pauli et al 1999</a>, <a class="bk_pop" href="#hops.REF.wenkert.2011.2389">Wenkert et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Infantile hypophosphatasia</b> cases may be normal at birth. Clinical signs may be recognized between birth and age six months and resemble rickets (<a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1A</a>). Open fontanels and wide sutures may be deceptive, in that the hypomineralized bone causing this radiographic appearance is prone to premature fusion. Craniosynostosis and intracranial hypertension are potential complications.</div><div class="half_rhythm">Clinical severity depends on the degree of pulmonary insufficiency; the infantile <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has high mortality, with 50% of individuals succumbing to respiratory failure caused by undermineralization of the ribs. Other complications include hypercalcemia, irritability, poor feeding, failure to thrive, hypotonia, and more rarely vitamin B<sub>6</sub>-dependent seizures (see <a href="#hops.Management">Management</a>). Older children may have renal damage.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Childhood (juvenile) hypophosphatasia</b> displays wide variability in clinical presentation, ranging from low bone mineral density for age with unexplained fractures to rickets. Children may have premature loss of deciduous teeth (age &#x0003c;5 years), usually beginning with incisors, with the dental root characteristically remaining attached to the lost tooth. More severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> toddlers have short stature and delay in walking, and develop a waddling myopathic gait. Bone and joint pain are typical. Diaphyseal and metaphyseal fractures may occur.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Adult hypophosphatasia</b> is sometimes associated with a history of transient rickets in childhood (&#x0201c;juvenile onset&#x0201d;) and/or premature loss of deciduous teeth. Early loss of adult dentition is common. Other dental problems in adolescents and adults with hypophosphatasia are more poorly characterized, although enamel hypoplasia and tooth mobility have been described.</div><div class="half_rhythm">Adult hypophosphatasia is usually recognized in middle age, the cardinal features being stress fractures and pseudofractures of the lower extremities. Foot pain and slow-to-heal stress fractures of the metatarsals are common. Thigh and hip pain may reflect pseudofractures ("Looser zones") in the lateral cortex of the femoral diaphysis (<a class="figpopup" href="/books/NBK1150/figure/hops.F1/?report=objectonly" target="object" rid-figpopup="fighopsF1" rid-ob="figobhopsF1">Figure 1C</a>). Chondrocalcinosis and osteoarthropathy may develop with age. Osteomalacia distinguishes adult hypophosphatasia from odontohypophosphatasia.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Odontohypophosphatasia</b> can be seen as an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> finding without additional abnormalities of the skeletal system or can be variably seen in the above forms of hypophosphatasia. Premature exfoliation of primary teeth and/or severe dental caries may be seen, with the incisors most frequently lost.</div></li></ul></div><div id="hops.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Most patients with hypophosphatasia have unique genotypes, making <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation difficult. However site-directed mutagenesis experiments identified alleles producing significant residual enzymatic activity and alleles showing a dominant negative effect (see <a href="#hops.Molecular_Genetics">Molecular Genetics</a>). Less severe phenotypes are correlated with alleles allowing residual enzymatic activity in recessive hypophosphatasia, and with alleles exhibiting a dominant negative effect in dominant hypophosphatasia [<a class="bk_pop" href="#hops.REF.fauvert.2009.51">Fauvert et al 2009</a>]. Clinical features of patients with reported variants, as well as residual enzyme activity for some of those variants, can be found at <a href="http://www.sesep.uvsq.fr/03_hypo_mutations.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sesep.uvsq.fr</a>.</p></div><div id="hops.Nomenclature"><h3>Nomenclature</h3><p>Hypophosphatasia takes its name from low activity of the enzyme alkaline phosphatase, rather than reflecting serum concentration of phosphorus.</p><p>In classifications of genetic conditions, hypophosphatasia may be considered a metabolic bone disease, a skeletal dysplasia, a metaphyseal dysplasia, a dental disorder, or a disorder of membrane-bound ectoenzyme activity in the extracellular matrix.</p></div><div id="hops.Prevalence"><h3>Prevalence</h3><p>Based on pediatric hospital records in Ontario, Canada, the birth prevalence of (<a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>) perinatal and infantile hypophosphatasia was estimated at 1:100,000 [<a class="bk_pop" href="#hops.REF.fraser.1957.730">Fraser 1957</a>].</p><p>Applying the Hardy-Weinberg equation to this estimate, the frequency of heterozygotes for <i>ALPL</i> pathogenic variants in Ontario, Canada is about 1:150.</p><p>In the Canadian Mennonite population, the prevalence of the perinatal (severe) form is 1:2500, for a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of 1:25.</p><p>On the basis of molecular diagnosis in France and in Europe, the prevalence of severe forms has been estimated at 1:300,000 [<a class="bk_pop" href="#hops.REF.mornet.2011.439">Mornet et al 2011</a>]. For mild forms (prenatal benign, childhood [juvenile], adult and odontohypophosphatasia), the prevalence is expected to be as high as 1:6300 [<a class="bk_pop" href="#hops.REF.mornet.2011.439">Mornet et al 2011</a>] because heterozygotes may express the disease with low selective pressure.</p><p>Applying the Hardy-Weinberg equation to this estimate for severe forms, the frequency of heterozygotes for <i>ALPL</i> pathogenic variants in France is about 1:275.</p><p>In Japan, the birth prevalence of severe hypophosphatasia may be estimated at 1:150,000 on the basis on the frequency of individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.1559delT (1:900,000 [<a class="bk_pop" href="#hops.REF.watanabe.2011.166">Watanabe et al 2011</a>]) and on the proportion of this <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in Japanese patients (40.9% [<a class="bk_pop" href="#hops.REF.michigami.2005.277">Michigami et al 2005</a>])</p><p>In China, some pathogenic variants have been reported [<a class="bk_pop" href="#hops.REF.wei.2010.1017">Wei et al 2010</a>, <a class="bk_pop" href="#hops.REF.zhang.2012.21">Zhang et al 2012</a>, <a class="bk_pop" href="#hops.REF.yang.2013.635">Yang et al 2013</a>] but the birth prevalence is unknown.</p><p>In Africa, no individuals with hypophosphatasia have been reported outside of North Africa; however, clinical ascertainment bias is likely significant. African American individuals with hypophosphatasia are rare; it is assumed that pathogenic variants in this population represent European admixture.</p></div></div><div id="hops.Genetically_Related_Allelic_Disorde"><h2 id="_hops_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>ALPL.</i></p></div><div id="hops.Differential_Diagnosis"><h2 id="_hops_Differential_Diagnosis_">Differential Diagnosis</h2><p>The differential diagnosis of hypophosphatasia depends on the age at which the diagnosis is considered. Clinical features that help differentiate hypophosphatasia from other conditions include bone hypomineralization prenatally and immediately postnatally; elevated serum concentrations of calcium and phosphorus postnatally; and of course, persistently low serum alkaline phosphatase enzyme activity.</p><p><b>In utero.</b> Early prenatal ultrasound examination may lead to a consideration of <a href="/books/n/gene/oi/">osteogenesis imperfecta</a> (OI) type II, <a href="/books/n/gene/campo-dysp/">campomelic dysplasia</a>, and chondrodysplasias with defects in bone mineralization, as well as hypophosphatasia. Experienced sonographers usually have little difficulty in distinguishing among these disorders. Fetal x-rays are sometimes helpful in recognizing the undermineralization of bone that is more typical of perinatal hypophosphatasia than the other disorders considered in the differential diagnosis.</p><p><b>At birth.</b> Outwardly difficult to distinguish, OI type II, <a href="/books/n/gene/td/">thanatophoric dysplasia</a>, campomelic dysplasia, and chondrodysplasias with bone mineralization defects are readily distinguished from hypophosphatasia by radiograph. In cases in which the diagnosis is in doubt, serum alkaline phosphatase activity and specialized biochemical testing (serum concentration of PLP or vitamin B<sub>6</sub>, urine concentration of PEA) can suggest the diagnosis pending confirmation with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p><p><b>Infancy and childhood.</b> Irritability, poor feeding, failure to thrive, hypotonia, and seizures place the <b>infantile type</b> in a broad differential diagnosis that includes inborn errors of energy metabolism, organic acidemia, primary and secondary rickets, neglect, and non-accidental trauma. Providing that appropriate pediatric normative reference values are used, <b>infantile hypophosphatasia</b> is suspected with low serum alkaline phosphatase enzyme activity, making the argument for routine screening of serum alkaline phosphatase enzyme activity in cases of failure to thrive, unexplained seizures, and suspected non-accidental skeletal injury.</p><ul><li class="half_rhythm"><div><b>Intractable seizures</b> may present prior to biochemical or radiographic manifestations of rickets in early hypophosphatasia.</div></li><li class="half_rhythm"><div><b>Rickets</b> defines the physical and radiographic features of early hypophosphatasia. However, whether caused by nutritional and/or vitamin D deficiency, vitamin D resistance, or renal osteodystrophy, rickets is readily distinguished from hypophosphatasia by laboratory findings. In rickets, the following are characteristic:</div><ul><li class="half_rhythm"><div>Elevated serum alkaline phosphatase activity</div></li><li class="half_rhythm"><div>Low serum concentrations of calcium and phosphorus</div></li><li class="half_rhythm"><div>Low serum concentrations of vitamin D</div></li><li class="half_rhythm"><div>Elevated serum concentration of parathyroid hormone</div></li></ul></li><li class="half_rhythm"><div><a href="/books/n/gene/oi/"><b>Osteogenesis imperfecta</b></a>
<b>(OI)</b> with deformation (typically type III in infancy or type IV later on) may resemble hypophosphatasia clinically.</div></li><li class="half_rhythm"><div><b>Dentinogenesis imperfecta (DI),</b> whether part of OI or an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> finding, is distinguishable from the dental presentation of hypophosphatasia.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/ccd/"><b>Cleidocranial dysostosis</b></a> is characterized by late closure of fontanels and cranial sutures, aplastic clavicles, delayed mineralization of the pubic rami, and delayed eruption of deciduous and permanent teeth. The skeletal dysplasia is distinguishable from hypophosphatasia on clinical examination and skeletal survey. The dental dysplasia does not result in early tooth loss, and the enamel hypoplasia is readily distinguishable from <b>odontohypophosphatasia</b>.</div></li><li class="half_rhythm"><div><b>Stuve-Wiedemann syndrome</b> (OMIM <a href="http://www.omim.org/entry/601559" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601559</a>) presents with temperature dysregulation, diminished reflexes, and contractures, but the severe perinatal presentation shares several features with hypophosphatasia: respiratory insufficiency, bowing of long bones, metaphyseal dysplasia, low bone density for age, and fracture predilection.</div></li><li class="half_rhythm"><div><b>Cole-Carpenter syndrome</b> (OMIM <a href="http://www.omim.org/entry/112240" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">112240</a>, <a href="http://www.omim.org/entry/616294" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616294</a>) is characterized by bone deformities, multiple fractures, proptosis, shallow orbits, orbital craniosynostosis, frontal bossing, and hydrocephalus.</div></li><li class="half_rhythm"><div><b>Hadju-Cheney syndrome</b> (OMIM <a href="http://www.omim.org/entry/102500" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">102500</a>) is characterized by failure to thrive, <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> facial features, early tooth loss, genitourinary anomalies, osteopenia, pathologic fractures, Wormian bones, failure of suture ossification, basilar impression, vertebral abnormalities, joint laxity, bowed fibulae, short distal digits, acroosteolysis, and hirsutism.</div></li><li class="half_rhythm"><div><b>Idiopathic juvenile osteoporosis (IJO)</b> (OMIM <a href="http://www.omim.org/entry/259750" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">259750</a>) typically presents in preadolescents with fractures and osteoporosis. The fracture susceptibility and osteoporosis usually resolve spontaneously with puberty. The etiology remains unknown.</div></li><li class="half_rhythm"><div><b>Renal osteodystrophy</b> may be confused with late presentation of the <b>childhood (juvenile) type</b> associated with renal damage; however, characteristic biochemical findings distinguish the two disorders.</div></li><li class="half_rhythm"><div><b>Non-accidental trauma (child abuse).</b> Like osteogenesis imperfecta, patient history, family history, physical examination, routine laboratories, radiographic imaging, and the clinical course all contribute to distinguishing hypophosphatasia from child abuse. Multiple fractures are less typical of hypophosphatasia. The family history may be particularly instructive in that the perinatal (severe) type is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder, and the childhood (juvenile), adult, and odontohypophosphatasia types are <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> disorders; all have been reported in a single family ascertained by unexplained fracture in a child [<a class="bk_pop" href="#hops.REF.liabaldini.2001.99">Lia-Baldini et al 2001</a>]. Serial measurement of serum alkaline phosphatase activity is usually sufficient to identify hypophosphatasia in this circumstance.</div></li><li class="half_rhythm"><div><b>Pseudohypophosphatasia</b> is characterized by clinical, biochemical, and radiographic findings reminiscent of infantile hypophosphatasia, with the exception that clinical laboratory assays of serum alkaline phosphatase activity are in the normal range.</div></li></ul><p><b>Adult and odontohypophosphatasia</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Osteoarthritis</b> and pseudogout (secondary to calcium pyrophosphate dehydrate deposition) are presentations of adult hypophosphatasia, distinguished from the more common disorders by clinical history and laboratory findings.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Osteopenia/osteoporosis</b> needs to be distinguished from adult hypophosphatasia, in that bisphosphonates may be contraindicated (see Management, <a href="#hops.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Periodontal disease</b> may be difficult to distinguish from hypophosphatasia, in that alveolar bone loss can be seen with severe gingivitis. However, gingival inflammation is unusual with odontohypophosphatasia. Familial periodontal disease can be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner (OMIM <a href="http://www.omim.org/entry/170650" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">170650</a>) or as part of a connective tissue disorder (e.g., <a href="/books/n/gene/eds4/">Ehlers-Danlos syndrome, vascular type</a> or Ehlers-Danlos syndrome, periodontal type VIII [OMIM <a href="http://omim.org/entry/130080" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">130080</a>]) or associated with neutropenia (e.g., <a href="/books/n/gene/cyclic-n/"><i>ELANE</i>-related neutropenia</a>). Ehlers-Danlos syndrome type VIII may present with root-intact tooth loss, the distinction being the low serum alkaline phosphatase of odontohypophosphatasia.</div><div class="half_rhythm">Rarer <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorders associated with premature tooth loss and periodontal disease include Papillon-Lefevre syndrome (OMIM <a href="http://omim.org/entry/245000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">245000</a>) and Haim-Munk syndrome (HMS) (OMIM <a href="http://omim.org/entry/245010" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">245010</a>), caused by pathogenic variants in <i>CTSC</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding dipeptidyl peptidase 1. The periodontal disease is usually earlier in onset and more severe than that seen with odontohypophosphatasia. Both Papillon-Lefevre syndrome and HMS are usually associated with palmar keratosis, further distinguishing them from odontohypophosphatasia. Measurement of serum alkaline phosphatase enzyme activity is reasonable when either disorder is considered.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Dentinogenesis imperfecta (DI).</b> Whether associated with osteogenesis imperfecta or as an <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> condition resulting from pathogenic variants in <i>DSPP</i> (OMIM <a href="http://omim.org/entry/125420" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">125420</a>) [<a class="bk_pop" href="#hops.REF.rajpar.2002.2559">Rajpar et al 2002</a>], DI is readily distinguishable from odontohypophosphatasia on biochemical findings.</div></li></ul></div><div id="hops.Management"><h2 id="_hops_Management_">Management</h2><div id="hops.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with hypophosphatasia, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Blood urea nitrogen and serum creatinine concentration to assess renal function</div></li><li class="half_rhythm"><div>Serum concentration of calcium, phosphorus, magnesium</div></li><li class="half_rhythm"><div>Serum concentration of 25(OH) and 1,25(OH)2 vitamin D, nPTH (parathyroid hormone, N-terminal part) to assess rickets</div></li><li class="half_rhythm"><div>Assessment of pulmonary function in infants with the perinatal type to assist in prognosis and distinguishing between the perinatal (severe) type and the perinatal (benign) type</div></li><li class="half_rhythm"><div>Radiographs of the skull to assess for craniosynostosis in young children with the infantile form of hypophosphatasia</div></li><li class="half_rhythm"><div>Baseline dental evaluation</div></li><li class="half_rhythm"><div>Baseline orthopedic evaluation</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hops.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management at all ages focuses on supportive therapy to minimize disease-related complications.</p><p>Multidisciplinary management at various ages may include:</p><ul><li class="half_rhythm"><div>Endocrinology to optimize bone homeostasis and avoid exacerbating treatments</div></li><li class="half_rhythm"><div>Nephrology to monitor calcium homeostasis and examine for nephrocalcinosis</div></li><li class="half_rhythm"><div>Neurology to prophylactically or prospectively treat seizures and manage myopathy</div></li><li class="half_rhythm"><div>Neurosurgery or craniofacial team to manage pseudocraniosynostosis</div></li><li class="half_rhythm"><div>Orthopedics to manage primary and secondary skeletal manifestations</div></li><li class="half_rhythm"><div>Physical medicine and rehabilitation (PM&#x00026;R), physical therapy, and occupational therapy to optimize mobility and autonomy</div></li><li class="half_rhythm"><div>Pain management</div></li><li class="half_rhythm"><div>Psychological support</div></li><li class="half_rhythm"><div>Pediatric and adult dentistry to manage tooth loss</div></li></ul><p>The involvement of multiple specialists treating complex interrelated medical issues mandates case management and social work support.</p><div id="hops.Enzyme_Replacement_Therapy"><h4>Enzyme Replacement Therapy</h4><p>The emergence of tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy (ERT) with asfotase alfa (Strensiq&#x02122;) has altered the natural history of severe perinatal and infantile HPP cases; the long-term effects of treatment are not fully known. A new <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of &#x0201c;treated perinatal and infantile HPP&#x0201d; is emerging, and the prior designation of &#x0201c;perinatal lethal HPP&#x0201d; may no longer universally apply in the developed world.</p><p>In October 2015, the FDA approved asfotase alfa for treatment of patients with perinatal, infantile, and juvenile onset HPP [<a href="http://news.alexionpharma.com/press-release/product-news/fda-approves-strensiq-asfotase-alfa-treatment-patients-perinatal-infantil" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alexion</a> &#x02013;10-23-2015].</p><ul><li class="half_rhythm"><div><b>Perinatal/infantile HPP study outcomes.</b> In two prospective, single-arm studies (with historical controls used for survival analysis), 68 individuals with severe, perinatal/infantile-onset HPP (age at treatment onset: 1 day &#x02013; 78 months) completed at least 24-weeks of TNSALP ERT (&#x02264;9 mg/kg weekly, administered subcutaneously) [<a class="bk_pop" href="#hops.REF.whyte.2016.334">Whyte et al 2016</a>] (<a href="http://strensiq.com/images/Strensiq_PRESCRIBING_INFORMATION.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">final data</a>).</div><ul><li class="half_rhythm"><div>Survival. Of those requiring respiratory support (n = 26), 21 (81%) survived through the last date of assessment (median age 3.2 years), in comparison to 1:20 (5%) in historical controls.</div></li><li class="half_rhythm"><div>In the mixed cohort of 68 patients with perinatal/infantile onset HPP receiving asfotase alfa ERT, 54 required mechanical ventilation and of these, 91% survived and 85% were ventilator free at last contact, in comparison to 27% overall survival and 25% ventilator free in the 48 historical controls [<a class="bk_pop" href="#hops.REF.whyte.2016.334">Whyte et al 2016</a>] (<a href="http://strensiq.com/images/Strensiq_PRESCRIBING_INFORMATION.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">final data</a>). Clinical trials with ERT have shown improvement in developmental milestones and pulmonary function [<a class="bk_pop" href="#hops.REF.whyte.2012.904">Whyte et al 2012</a>].</div></li><li class="half_rhythm"><div>Bone findings. Radiographs from 64 of these individuals, and four from a third prospective open-label study of juvenile-onset HPP, were evaluated for HPP-related rickets using the 7-point Radiographic Global Impression of Change (RGI-C) scale. Radiographic change of at least +2 (defined as &#x0201c;responders&#x0201d;) were seen in 50/68 (74%) of those treated (see <a class="figpopup" href="/books/NBK1150/figure/hops.F2/?report=objectonly" target="object" rid-figpopup="fighopsF2" rid-ob="figobhopsF2">Figure 2</a>), at last assessment (historical comparative data does not exist). Eighteen individuals with perinatal/infantile-onset HPP experienced fractures during the course of treatment; the effect of asfotase alfa on fractures remaining unclear [<a class="bk_pop" href="#hops.REF.whyte.2016.334">Whyte et al 2016</a>] (<a href="http://strensiq.com/images/Strensiq_PRESCRIBING_INFORMATION.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">final data</a>).</div></li></ul></li><li class="half_rhythm"><div><b>Juvenile-onset HPP study outcomes.</b> One prospective open-label, single arm study included eight patients with juvenile-onset HPP and five patients with perinatal/infantile-onset HPP; age at treatment onset was six to 12 years. The patients with juvenile-onset HPP completed at least 48 months of TNSALP ERT (6 mg/kg weekly, administered subcutaneously). The eight juvenile-onset patients were compared with 32 historical controls. By the RGI-C rating of radiographs, all eight patients were deemed responders; two (6%) of the historical controls were rated responders with an improvement of +2 or more at month 54. Gait, assessed using a modified Performance Oriented Mobility Assessment Gait (MPOMA-G), six-minute walk test (6MWT), and step length improved in patients treated with asfotase alfa. 6MWT improved to the normal range in six of six patients assessed by month 48, from none at baseline. The data are at present insufficient to assess the effect of asfotase alfa on fractures in juvenile-onset HPP [<a class="bk_pop" href="#hops.REF.whyte.2016.334">Whyte et al 2016</a>] (<a href="http://strensiq.com/images/Strensiq_PRESCRIBING_INFORMATION.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">final data</a>).</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighopsF2" co-legend-rid="figlgndhopsF2"><a href="/books/NBK1150/figure/hops.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="fighopsF2" rid-ob="figobhopsF2"><img class="small-thumb" src="/books/NBK1150/bin/hops-Image002.gif" src-large="/books/NBK1150/bin/hops-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndhopsF2"><h4 id="hops.F2"><a href="/books/NBK1150/figure/hops.F2/?report=objectonly" target="object" rid-ob="figobhopsF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Radiograph of treated hypophosphatasia A. Patient from Figure 1A after 12 months asfotase alfa enzyme replacement therapy</p></div></div></div><div id="hops.When_Enzyme_Replacement_Therapy_is"><h4>When Enzyme Replacement Therapy is Not Available or Not Typically Used</h4><p><b>Perinatal types.</b> Limited experience exists for asfotase alfa ERT treatment of perinatal HPP in the immediate newborn period, and this therapy may not be readily available. In the immediate perinatal period, if multidisciplinary assessment identifies the perinatal severe type, comfort care and supportive management of infant and family remain an option.</p><p><b>Infantile type.</b> The infantile <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has high mortality, with 50% of individuals succumbing to respiratory failure caused by undermineralization of the ribs. In the absence of ERT, supportive management remains.</p><ul><li class="half_rhythm"><div>Calcium homeostasis. Management can further be complicated by recalcitrant hypercalcemia/hypercalciuria, and optimal management of this issue remains unclear: hypercalcemia/hypercalciuria is typically resistant to hydration and furosemide treatment, and bisphosphonates would be contraindicated (see <a href="#hops.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>). In the absence of ERT, calcitonin and steroids could be attempted short term, with limited efficacy [<a class="bk_pop" href="#hops.REF.deeb.2000.730">Deeb et al 2000</a>].</div></li><li class="half_rhythm"><div>Seizures. When present, seizures may respond to treatment with vitamin B<sub>6</sub> (pyridoxine). Pyridoxal phosphate (PLP), one of the natural substrates of alkaline phosphatase, is the active compound by which pyridoxine mediates essential enzyme activity; PLP deficiency in the central nervous system may reduce seizure threshold by reducing neurotransmitter (GABA) synthesis.</div></li><li class="half_rhythm"><div>Craniosynostosis in those with the infantile <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is variable. When identified, involvement of a neurosurgeon to monitor for complications is prudent. Increased intracranial pressure secondary to craniosynostosis is an indication for surgical release.</div></li><li class="half_rhythm"><div>Dental care beginning at age one year is important to preserve primary dentition (to support nutrition) and to preserve or replace secondary dentition.</div></li></ul><p><b>Childhood (juvenile) and adult hypophosphatasia</b></p><ul><li class="half_rhythm"><div>Osteoarthritis may respond to NSAIDs.</div></li><li class="half_rhythm"><div>Bone pain and osteomalacia are managed supportively: NSAIDs appear beneficial [<a class="bk_pop" href="#hops.REF.girschick.2006.24">Girschick et al 2006</a>]. Hypophosphatasia is a relative contraindication to treatment with bisphosphonates (see <a href="#hops.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</div></li><li class="half_rhythm"><div>Pseudofractures and stress fractures are difficult to manage; internal fixation has been suggested as the optimal orthopedic management. Foot orthotics may help in management of tarsal fractures and pseudofractures in adults.</div></li></ul></div></div><div id="hops.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Low-impact physical activity and exercise may improve general bone health. Supervision by a physician specialist familiar with hypophosphatasia is suggested.</p></div><div id="hops.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Calcium supplementation and vitamin D therapy may prevent secondary hyperparathyroidism in adults. This should only be pursued with close monitoring by a physician specialist familiar with hypophosphatasia.</p></div><div id="hops.Surveillance"><h3>Surveillance</h3><p>Children with hypophosphatasia should be seen by a pediatric dentist twice yearly, beginning at age one year.</p><p>Children with the infantile type of hypophosphatasia are at elevated risk for increased intracranial pressure secondary to craniosynostosis, and should be monitored for this complication.</p></div><div id="hops.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p><b>Biphosphonates</b> are relatively contraindicated in hypophosphatasia. Although adverse outcomes have not been identified in children with the severe infantile type [<a class="bk_pop" href="#hops.REF.deeb.2000.730">Deeb et al 2000</a>], theoretic concern has long been raised based on the structure of bisphosphonates. The phosphate motifs in bisphosphonates have a similar conformation to inorganic pyrophosphate (PPi), the natural substrate of TNSALP; thus, treatment with bisphosphonates is thought to be analogous to "adding fuel to the fire." In adults with hypophosphatasia and osteomalacia treated with bisphosphonates, lateral subtrochanteric femoral pseudofractures have been described [<a class="bk_pop" href="#hops.REF.whyte.2009.1132">Whyte 2009</a>]. As the prevalence of adult hypophosphatasia is not known and many undiagnosed adult patients undoubtedly are treated with bisphosphonates, the frequency of this unusual complication is not known.</p><p><b>Excess vitamin D</b> can exacerbate hypercalcemia/hypercalciuria in children with infantile hypophosphatasia who have hypercalcemia.</p><p><b>Teriparatide</b> (recombinant human parathyroid hormone fragment, amino acids 1-34) at high doses induces osteosarcoma in rats, and may increase the risk of radiation-induced osteosarcoma (a pediatric growth plate tumor) in humans. It is contraindicated in children with hypophosphatasia.</p></div><div id="hops.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#hops.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hops.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p><b>Enzyme replacement therapy (ERT).</b> Autosomal recessive hypophosphatasia remains an extremely rare and severe condition. The treatment duration and long-term effects of ERT with asfotase alfa remain unknown for perinatal and infantile HPP. Clinical trials are in Phase IV, with patients treated up to 78 months at the time of FDA approval.</p><p>For milder <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> childhood (juvenile) and adult-onset HPP, limited information about asfotase alfa exists; clinical trials are underway in children, adolescents, and adults.</p><p><b>Bone marrow transplantation</b> (hematopoietic cell transplantation) was used to treat an eight-month-old girl with severe hypophosphatasia with prolonged, significant clinical and radiologic improvement [<a class="bk_pop" href="#hops.REF.whyte.2003.624">Whyte et al 2003</a>]. Seven years after transplantation, the patient was reported to be active and growing, and to have the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of the more mild childhood (juvenile) form of hypophosphatasia [<a class="bk_pop" href="#hops.REF.cahill.2007.2923">Cahill et al 2007</a>]. In another trial, both bone marrow and allogenic mesenchymal stem cells were implanted in an eight-month old patient, resulting in improvement of respiratory conditions [<a class="bk_pop" href="#hops.REF.tadokoro.2009.924">Tadokoro et al 2009</a>]. However,the patient developed therapy-related leukemia [<a class="bk_pop" href="#hops.REF.taketani.2013.e52">Taketani et al 2013</a>]. Transplantation of ex vivo expanded mesenchymal stem cells for patients who had previously undergone bone marrow transplantation improved bone mineralization, muscle mass, respiratory function, intellectual development, and survival [<a class="bk_pop" href="#hops.REF.taketani.2015.1931">Taketani et al 2015</a>].</p><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="hops.Genetic_Counseling"><h2 id="_hops_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hops.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Perinatal and most infantile cases of infantile hypophosphatasia are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p>Milder forms of hypophosphatasia, especially adult and odontohypophosphatasia, may be inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> or <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner depending on the effect of the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on TNSALP activity [<a class="bk_pop" href="#hops.REF.fauvert.2009.51">Fauvert et al 2009</a>].</p></div><div id="hops.Risk_to_Family_Members__Autosomal_R"><h3>Risk to Family Members &#x02013; Autosomal Recessive Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>In most cases, the parents of a child with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> form of hypophosphatasia are obligate heterozygotes (i.e., carriers of one <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>In extremely rare cases, only one parent of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><ul><li class="half_rhythm"><div><a class="bk_pop" href="#hops.REF.taillandier.2005.2436">Taillandier et al [2005]</a> and <a class="bk_pop" href="#hops.REF.zhang.2012.21">Zhang et al [2012]</a> each reported one case of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the second <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> in an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> hypophosphatasia.</div></li><li class="half_rhythm"><div>Uniparental disomy of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 1 was reported as the cause of recessive hypophosphatasia in two cases [<a class="bk_pop" href="#hops.REF.watanabe.2014.93">Watanabe et al 2014</a>, <a class="bk_pop" href="#hops.REF.hancarova.2015.765">Hancarova et al 2015</a>].</div></li></ul></li><li class="half_rhythm"><div>Depending on the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parents are either clinically asymptomatic (manifesting only biochemical abnormality) or have milder clinical symptoms than their child. Determining the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> in families with mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parents is difficult and may lead to consideration of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and a 25% chance of being unaffected and not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li><li class="half_rhythm"><div>Depending on the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> sibs can be either clinically asymptomatic (manifesting only biochemical abnormality) or have milder clinical symptoms than the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> hypophosphatasia are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ALPL</i>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ALPL</i>.</p></div><div id="hops.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>ALPL</i> pathogenic variants in the family.</p></div><div id="hops.Risk_to_Family_Members__Autosomal_D"><h3>Risk to Family Members &#x02013; Autosomal Dominant Inheritance</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, all reported individuals diagnosed with the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of hypophosphatasia have inherited an <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a parent (who may or may not have symptoms).</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of hypophosphatasia has not been reported to date.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> include review of clinical history and laboratory evaluations for signs of hypophosphatasia. Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of failure by health care professionals to recognize the syndrome, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, and/or a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the pathogenic variant is 50%. Clinical severity is often similar in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members but cannot be reliably predicted by family history or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> due to reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> and <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with the <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> form of hypophosphatasia has a 50% chance of inheriting the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has an <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="hops.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Determining the <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></b> can be difficult in some families as expression of the disease may be highly variable, with parents of even markedly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children showing no or extremely mild symptoms of the disease.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hops.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><div id="hops.Pregnancy_with_high_a_priori_risk_p"><h4>Pregnancy with high a priori risk (pregnancy known to be at increased risk based on family history)</h4><p><b>Molecular genetic testing.</b> Once the <i>ALPL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>(s) have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for hypophophatasia are possible.</p><p><b>Fetal ultrasonography.</b> Recurrence of perinatal hypophosphatasia may reliably be identified by prenatal ultrasound examination. Undermineralization, small thoracic cavity, shortened long bones, and bowing are typical features of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and severe hypophosphatasia. Long bone bowing has been reported prenatally in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs and in children of individuals with childhood (juvenile) or adult hypophosphatasia, but the finding is not diagnostic of perinatal hypophosphatasia since it may be prenatal benign hypophosphatasia, a clinical form that can improve during later stages of pregnancy and result in nonlethal hypophosphatasia [<a class="bk_pop" href="#hops.REF.moore.1999.410">Moore et al 1999</a>, <a class="bk_pop" href="#hops.REF.pauli.1999.434">Pauli et al 1999</a>, <a class="bk_pop" href="#hops.REF.wenkert.2011.2389">Wenkert et al 2011</a>].</p><p><b>Biochemical testing.</b> Concentration of alkaline phosphatase in amniotic fluid, amniocytes, and chorionic villous samples is prone to misinterpretation (particularly in distinguishing unaffected heterozygotes); <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is the preferred method in confirming <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> [<a class="bk_pop" href="#hops.REF.mornet.1999.755">Mornet et al 1999</a>].</p></div><div id="hops.Pregnancy_with_low_a_priori_risk_pr"><h4>Pregnancy with low a priori risk (pregnancy not known to be at risk)</h4><p><b>Fetal ultrasonography.</b> Although perinatal hypophosphatasia may be distinguished from other skeletal dysplasias by prenatal ultrasonography, care must be taken in the interpretation of bowed long bones. Undermineralization, small thoracic cavity, shortened long bones, and bowing are typical features of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> and severe hypophosphatasia. However, prognosis is difficult to predict based on ultrasound findings alone. Bowed and shortened long bones have been observed on prenatal ultrasound in individuals who ultimately were shown to have benign perinatal, childhood (juvenile), and adult hypophosphatasia. The bowing resolves postnatally. In 50% of the cases, when <i>ALPL</i> molecular testing has been performed, a single <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ALPL</i> has been identified, confirming the benign nature of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and excluding perinatal (severe) hypophosphatasia.</p></div></div></div><div id="hops.Resources"><h2 id="_hops_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>HypoPhosPhatasia Support Association of Japan (HPPSA-J)</b></div><div><a href="http://hypophosphatasia.life.coocan.jp/english/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hypophosphatasia.life.coocan.jp</a></div></li><li class="half_rhythm"><div><b>Hypophosphatasie Europe</b></div><div>16 rue Barban&#x000e8;gre</div><div>Huningue 68330</div><div>France</div><div><b>Email:</b> contact@hypophosphatasie.com</div><div><a href="http://www.hypophosphatasie.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hypophosphatasie.com</a></div></li><li class="half_rhythm"><div><b>MAGIC Foundation</b></div><div>6645 West North Avenue</div><div>Oak Park IL 60302</div><div><b>Phone:</b> 800-362-4423; 708-383-0808</div><div><b>Fax:</b> 708-383-0899</div><div><b>Email:</b> ContactUs@magicfoundation.org</div><div><a href="https://www.magicfoundation.org/Growth-Disorders/Hypophosphatasia/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hypophosphatasia</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Hypophosphatasia&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hypophosphatasia</a></div></li><li class="half_rhythm"><div><b>Soft Bones Canada</b></div><div>PO Box 882</div><div>Winkler Manitoba R6W 4A9</div><div>Canada</div><div><b>Phone:</b> 204-202-3211</div><div><b>Email:</b> contactus@softbonescanada.ca</div><div><a href="http://softbonescanada.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.softbonescanada.ca</a></div></li><li class="half_rhythm"><div><b>Soft Bones, Inc.</b></div><div>121 Hawkins Place #267</div><div>Boonton NJ 07005</div><div><b>Phone:</b> 866-827-9937</div><div><a href="http://www.softbones.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.softbones.org</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div>RareCareSM</div><div><b>Phone:</b> 800-999-6673</div><div><a href="https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs-2/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Assistance Programs</a></div></li><li class="half_rhythm"><div><b>International Skeletal Dysplasia Registry</b></div><div>UCLA</div><div>615 Charles E. Young Drive</div><div>South Room 410</div><div>Los Angeles CA 90095-7358</div><div><b>Phone:</b> 310-825-8998</div><div><b>Fax:</b> 310-206-5266</div><div><b>Email:</b> Salon@mednet.ucla.edu</div><div><a href="https://www.uclahealth.org/ortho/isdr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Skeletal Dysplasia Registry</a></div></li></ul></div><div id="hops.Molecular_Genetics"><h2 id="_hops_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hops.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hypophosphatasia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1150/table/hops.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hops.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hops.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hops.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hops.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hops.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hops.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hops.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hops.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/249" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ALPL</i></a></td><td headers="hd_b_hops.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=249" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1p36<wbr style="display:inline-block"></wbr>​.12</a></td><td headers="hd_b_hops.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P05186" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alkaline phosphatase, tissue-nonspecific isozyme</a></td><td headers="hd_b_hops.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.sesep.uvsq.fr/Database.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tissue Nonspecific Alkaline Phosphatase Gene Mutation Database</a><br /><a href="http://databases.lovd.nl/shared/genes/ALPL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALPL database</a></td><td headers="hd_b_hops.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ALPL" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALPL</a></td><td headers="hd_b_hops.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ALPL[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ALPL</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hops.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hops.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hypophosphatasia (<a href="/omim/146300,171760,241500,241510" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1150/table/hops.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hops.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/146300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">146300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPOPHOSPHATASIA, ADULT</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/171760" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">171760</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALKALINE PHOSPHATASE, LIVER; ALPL</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/241500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">241500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPOPHOSPHATASIA, INFANTILE</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/241510" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">241510</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HYPOPHOSPHATASIA, CHILDHOOD</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> consists of 12 exons: 11 coding exons and one untranslated <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>. For a detailed summary of gene and protein information, see <a href="/books/NBK1150/#hops.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Three benign variants are <a class="figpopup" href="/books/NBK1150/table/hops.T.selected_alpl_variants/?report=objectonly" target="object" rid-figpopup="fighopsTselectedalplvariants" rid-ob="figobhopsTselectedalplvariants">c.455G&#x0003e;A</a>, <a class="figpopup" href="/books/NBK1150/table/hops.T.selected_alpl_variants/?report=objectonly" target="object" rid-figpopup="fighopsTselectedalplvariants" rid-ob="figobhopsTselectedalplvariants">c.787T&#x0003e;C</a>, and <a class="figpopup" href="/books/NBK1150/table/hops.T.selected_alpl_variants/?report=objectonly" target="object" rid-figpopup="fighopsTselectedalplvariants" rid-ob="figobhopsTselectedalplvariants">c.1565T&#x0003e;C</a>. A number of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> and <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> sequence variations have been reported as polymorphisms in the <a href="http://www.sesep.uvsq.fr/03_hypo_mutations.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>ALPL</i> Mutation Database</a>.</p><p><b>Pathogenic variants.</b> More than 300 distinct pathogenic variants in <i>ALPL</i> have been described, mostly in persons from North America, Japan, and Europe. A continually updated list of pathogenic variants is available online; see <a href="http://www.sesep.uvsq.fr/03_hypo_mutations.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.sesep.uvsq.fr</a>. (See also <a href="/books/NBK1150/#hops.molgen.TA">Table A</a>.)</p><p>The pathogenic variants are distributed throughout the 12 exons of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants account for 74.6% of variants; the remainder comprise microdeletions/insertions (13.3%), pathogenic <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants (6.0%), pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants (3.7%), gross deletions (1.3%), and a nucleotide substitution affecting the major transcription initiation site. This variety of pathogenic variants results in highly variable clinical expression and in a great number of <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> genotypes.</p><div id="hops.T.selected_alpl_variants" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Selected <i>ALPL</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1150/table/hops.T.selected_alpl_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hops.T.selected_alpl_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hops.T.selected_alpl_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_hops.T.selected_alpl_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_hops.T.selected_alpl_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_hops.T.selected_alpl_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.455G&#x0003e;A</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg152His</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_4" rowspan="8" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000478.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000478<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000469.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000469<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.787T&#x0003e;C</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr263His</td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1565T&#x0003e;C</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val522Ala</td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.571G&#x0003e;A</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu191Lys</td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.979T&#x0003e;C</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe327Leu</td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1001G&#x0003e;A</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly334Asp</td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1133A&#x0003e;T</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp378Val</td></tr><tr><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1559delT</td><td headers="hd_h_hops.T.selected_alpl_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu520ArgfsTer86</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">The amino acid residues are numbered from the beginning of the signal peptide sequence.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>. <i>ALPL</i> encodes alkaline phosphatase, tissue-nonspecific isozyme (TNSALP), the isozyme present in liver, kidney, and bone. Alkaline phosphatase comprises 524 amino acids, with a signal peptide of 17 amino acids and a mature peptide of 507. It is functional as a homodimer.</p><p>The enzyme acts as a (lipid) membrane-bound ectophosphatase with PPi, PLP, and PEA as natural substrates.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants may result in various consequences, sometimes cumulative: decrease or abolition of the catalytic activity; inability to form homodimers; sequestration of mutated proteins in cell compartments resulting in an inability to reach the cell membrane, its final destination for physiologic activity [<a class="bk_pop" href="#hops.REF.cai.1998.3936">Cai et al 1998</a>, <a class="bk_pop" href="#hops.REF.fukushi.1998.613">Fukushi et al 1998</a>, <a class="bk_pop" href="#hops.REF.shibata.1998.968">Shibata et al 1998</a>, <a class="bk_pop" href="#hops.REF.watanabe.2002.1945">Watanabe et al 2002</a>, <a class="bk_pop" href="#hops.REF.brunheath.2007.367">Brun-Heath et al 2007</a>, <a class="bk_pop" href="#hops.REF.sultana.2013.282">Sultana et al 2013</a>, <a class="bk_pop" href="#hops.REF.numakinjoh.2015.180">Numa-Kinjoh et al 2015</a>].</p><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations have been studied by the use of site-directed mutagenesis and 3D modeling of the enzyme. These studies allowed the characterization of severe and moderate alleles (alleles producing significant residual enzymatic activity) and alleles with a dominant negative effect responsible for dominant inheritance [<a class="bk_pop" href="#hops.REF.fukushi.1998.613">Fukushi et al 1998</a>, <a class="bk_pop" href="#hops.REF.shibata.1998.968">Shibata et al 1998</a>, <a class="bk_pop" href="#hops.REF.zurutuza.1999.1039">Zurutuza et al 1999</a>, <a class="bk_pop" href="#hops.REF.mornet.2001.31171">Mornet et al 2001</a>, <a class="bk_pop" href="#hops.REF.watanabe.2002.1945">Watanabe et al 2002</a>, <a class="bk_pop" href="#hops.REF.nasu.2006.5612">Nasu et al 2006</a>, <a class="bk_pop" href="#hops.REF.brunheath.2007.367">Brun-Heath et al 2007</a>, <a class="bk_pop" href="#hops.REF.fauvert.2009.51">Fauvert et al 2009</a>]. However, such tools do not reliably predict the severity of pathogenic variants.</p></div><div id="hops.References"><h2 id="_hops_References_">References</h2><div id="hops.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hops.REF.brunheath.2007.367">Brun-Heath I, Lia-Baldini AS, Maillard S, Taillandier A, Utsch B, Nunes ME, Serre JL, Mornet E. Delayed transport of tissue-nonspecific alkaline phosphatase with missense mutations causing hypophosphatasia. <span><span class="ref-journal">Eur J Med Genet. </span>2007;<span class="ref-vol">50</span>:367–78.</span> [<a href="/pubmed/17719863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17719863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.cahill.2007.2923">Cahill RA, Wenkert D, Perlman SA, Steele A, Coburn SP, McAlister WH, Mumm S, Whyte MP. Infantile hypophosphatasia: transplantation therapy trial using bone fragments and cultured osteoblasts. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007;<span class="ref-vol">92</span>:2923–30.</span> [<a href="/pubmed/17519318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17519318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.cai.1998.3936">Cai G, Michigami T, Yamamoto T, Yasui N, Satomura K, Yamagata M, Shima M, Nakajima S, Mushiake S, Okada S, Ozono K. Analysis of localization of mutated tissue-nonspecific alkaline phosphatase proteins associated with neonatal hypophosphatasia using green fluorescent protein chimeras. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1998;<span class="ref-vol">83</span>:3936–42.</span> [<a href="/pubmed/9814472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9814472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.colantonio.2012.854">Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, Pasic MD, Armbruster D, Adeli K. Closing the gaps in pediatric laboratory reference intervals: A CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. <span><span class="ref-journal">Clin Chem. </span>2012;<span class="ref-vol">58</span>:854–68.</span> [<a href="/pubmed/22371482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22371482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.cole.1986.992">Cole DE, Salisbury SR, Stinson RA, Coburn SP, Ryan LM, Whyte MP. Increased serum pyridoxal-5'-phosphate in pseudohypophosphatasia. <span><span class="ref-journal">N Engl J Med. </span>1986;<span class="ref-vol">314</span>:992–3.</span> [<a href="/pubmed/3960066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3960066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.deeb.2000.730">Deeb AA, Bruce SN, Morris AA, Cheetham TD. Infantile hypophosphatasia: disappointing results of treatment. <span><span class="ref-journal">Acta Paediatr. </span>2000;<span class="ref-vol">89</span>:730–3.</span> [<a href="/pubmed/10914973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10914973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.fauvert.2009.51">Fauvert D, Brun-Heath I, Lia-Baldini AS, Bellazi L, Taillandier A, Serre JL, de Mazancourt P, Mornet E. Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles. <span><span class="ref-journal">BMC Med Genet. </span>2009;<span class="ref-vol">10</span>:51.</span> [<a href="/pmc/articles/PMC2702372/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2702372</span></a>] [<a href="/pubmed/19500388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19500388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.fraser.1957.730">Fraser D. Hypophosphatasia. <span><span class="ref-journal">Am J Med. </span>1957;<span class="ref-vol">22</span>:730–46.</span> [<a href="/pubmed/13410963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13410963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.fukushi.1998.613">Fukushi M, Amizuka N, Hoshi K, Ozawa H, Kumagai H, Omura S, Misumi Y, Ikehara Y, Oda K. Intracellular retention and degradation of tissue-nonspecific alkaline phosphatase with a Gly317--&#x0003e;Asp substitution associated with lethal hypophosphatasia. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>1998;<span class="ref-vol">246</span>:613–8.</span> [<a href="/pubmed/9618260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9618260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.girschick.2006.24">Girschick HJ, Schneider P, Haubitz I, Hiort O, Collmann H, Beer M, Shin YS, Seyberth HW. Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2006;<span class="ref-vol">1</span>:24.</span> [<a href="/pmc/articles/PMC1533806/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1533806</span></a>] [<a href="/pubmed/16803637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16803637</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.hancarova.2015.765">Hancarova M, Krepelova A, Puchmajerova A, Soucek O, Prchalova D, Sumnik Z, Sedlacek Z. Hypophosphatasia due to uniparental disomy. <span><span class="ref-journal">Bone. </span>2015;<span class="ref-vol">81</span>:765–6.</span> [<a href="/pubmed/25937451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25937451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.liabaldini.2001.99">Lia-Baldini AS, Muller F, Taillandier A, Gibrat JF, Mouchard M, Robin B, Simon-Bouy B, Serre JL, Aylsworth AS, Bieth E, Delanote S, Freisinger P, Hu JC, Krohn HP, Nunes ME, Mornet E. A molecular approach to dominance in hypophosphatasia. <span><span class="ref-journal">Hum Genet. </span>2001;<span class="ref-vol">109</span>:99–108.</span> [<a href="/pubmed/11479741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11479741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.michigami.2005.277">Michigami T, Uchihashi T, Suzuki A, Tachikawa K, Nakajima S, Ozono K. Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia. <span><span class="ref-journal">Eur J Pediatr. </span>2005;<span class="ref-vol">164</span>:277–82.</span> [<a href="/pubmed/15660230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15660230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.moore.1999.410">Moore CA, Curry CJ, Henthorn PS, Smith JA, Smith JC, O'Lague P, Coburn SP, Weaver DD, Whyte MP. Mild autosomal dominant hypophosphatasia: in utero presentation in two families. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">86</span>:410–5.</span> [<a href="/pubmed/10508980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10508980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.mornet.2015">Mornet E. The Tissue Nonspecific Alkaline Gene Mutation Database. Available <a href="http://www.sesep.uvsq.fr/03_hypo_mutations.php" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2015. Accessed 4-30-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.mornet.1999.755">Mornet E, Muller F, Ngo S, Taillandier A, Simon-Bouy B, Maire I, Oury JF. Correlation of alkaline phosphatase (ALP) determination and analysis of the tissue non-specific ALP gene in prenatal diagnosis of severe hypophosphatasia. <span><span class="ref-journal">Prenat Diagn. </span>1999;<span class="ref-vol">19</span>:755–7.</span> [<a href="/pubmed/10451522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10451522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.mornet.2001.31171">Mornet E, Stura E, Lia-Baldini AS, Stigbrand T, Menez A, Le Du MH. Structural evidence for a functional role of human tissue nonspecific alkaline phosphatase in bone mineralization. <span><span class="ref-journal">J Biol Chem. </span>2001;<span class="ref-vol">276</span>:31171–8.</span> [<a href="/pubmed/11395499" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11395499</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.mornet.2011.439">Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. <span><span class="ref-journal">Ann Hum Genet. </span>2011;<span class="ref-vol">75</span>:439–45.</span> [<a href="/pubmed/21488855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21488855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.nasu.2006.5612">Nasu M, Ito M, Ishida Y, Numa N, Komaru K, Nomura S, Oda K. Aberrant interchain disulfide bridge of tissue-nonspecific alkaline phosphatase with an Arg433--&#x0003e;Cys substitution associated with severe hypophosphatasia. <span><span class="ref-journal">FEBS J. </span>2006;<span class="ref-vol">273</span>:5612–24.</span> [<a href="/pubmed/17212778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17212778</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.numakinjoh.2015.180">Numa-Kinjoh N, Komaru K, Ishida Y, Sohda M, Oda K. Molecular phenotype of tissue-nonspecific alkaline phosphatase with a proline (108) to leucine substitution associated with dominant odontohypophosphatasia. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">115</span>:180–5.</span> [<a href="/pubmed/25982064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25982064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.pauli.1999.434">Pauli RM, Modaff P, Sipes SL, Whyte MP. Mild hypophosphatasia mimicking severe osteogenesis imperfecta in utero: bent but not broken. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">86</span>:434–8.</span> [<a href="/pubmed/10508985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10508985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.rajpar.2002.2559">Rajpar MH, Koch MJ, Davies RM, Mellody KT, Kielty CM, Dixon MJ. Mutation of the signal peptide region of the bicistronic gene DSPP affects translocation to the endoplasmic reticulum and results in defective dentine biomineralization. <span><span class="ref-journal">Hum Mol Genet. </span>2002;<span class="ref-vol">11</span>:2559–65.</span> [<a href="/pubmed/12354781" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12354781</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.shibata.1998.968">Shibata H, Fukushi M, Igarashi A, Misumi Y, Ikehara Y, Ohashi Y, Oda K. Defective intracellular transport of tissue-nonspecific alkaline phosphatase with an Ala162--&#x0003e;Thr mutation associated with lethal hypophosphatasia. <span><span class="ref-journal">J Biochem (Tokyo). </span>1998;<span class="ref-vol">123</span>:968–77.</span> [<a href="/pubmed/9562633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9562633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.spentchian.2006.252">Spentchian M, Brun-Heath I, Taillandier A, Fauvert D, Serre JL, Simon-Bouy B, Carvalho F, Grochova I, Mehta SG, M&#x000fc;ller G, Oberstein SL, Ogur G, Sharif S, Mornet E. Characterization of missense mutations and large deletions in the ALPL gene by sequencing and quantitative multiplex PCR of short fragments. <span><span class="ref-journal">Genet Test. </span>2006;<span class="ref-vol">10</span>:252–7.</span> [<a href="/pubmed/17253930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17253930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.sultana.2013.282">Sultana S, Al-Shawafi HA, Makita S, Sohda M, Amizuka N, Takagi R, Oda K. An asparagine at position 417 of tissue-nonspecific alkaline phosphatase is essential for its structure and function as revealed by analysis of the N417S mutation associated with severe hypophosphatasia. <span><span class="ref-journal">Mol Genet Metab. </span>2013;<span class="ref-vol">109</span>:282–8.</span> [<a href="/pubmed/23688511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23688511</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.tadokoro.2009.924">Tadokoro M, Kanai R, Taketani T, Uchio Y, Yamaguchi S, Ohgushi H. New bone formation by allogeneic mesenchymal stem cell transplantation in a patient with perinatal hypophosphatasia. <span><span class="ref-journal">J Pediatr. </span>2009;<span class="ref-vol">154</span>:924–30.</span> [<a href="/pubmed/19446101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19446101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.taillandier.2005.2436">Taillandier A, Sallinen SL, Brun-Heath I, De Mazancourt P, Serre JL, Mornet E. Childhood hypophosphatasia due to a de novo missense mutation in the tissue-nonspecific alkaline phosphatase gene. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2005;<span class="ref-vol">90</span>:2436–9.</span> [<a href="/pubmed/15671102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15671102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.taketani.2013.e52">Taketani T, Kanai R, Abe M, Mishima S, Tadokoro M, Katsube Y, Yuba S, Ogushi H, Fukuda S, Yamaguchi S. Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia. <span><span class="ref-journal">Pediatr Int. </span>2013;<span class="ref-vol">55</span>:e52–5.</span> [<a href="/pubmed/23782379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23782379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.taketani.2015.1931">Taketani T, Oyama C, Mihara A, Tanabe Y, Abe M, Hirade T, Yamamoto S, Bo R, Kanai R, Tadenuma T, Michibata Y, Yamamoto S, Hattori M, Katsube Y, Ohnishi H, Sasao M, Oda Y, Hattori K, Yuba S, Ohgushi H, Yamaguchi S. Ex vivo expanded allogeneic mesenchymal stem cells with bone marrow transplantation improved osteogenesis in infants with severe hypophosphatasia. <span><span class="ref-journal">Cell Transplant. </span>2015;<span class="ref-vol">24</span>:1931–43.</span> [<a href="/pubmed/25396326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25396326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.watanabe.2002.1945">Watanabe H, Goseki-Sone M, Orimo H, Hamatani R, Takinami H, Ishikawa I. Function of mutant (G1144A) tissue-nonspecific ALP gene from hypophosphatasia. <span><span class="ref-journal">J Bone Miner Res. </span>2002;<span class="ref-vol">17</span>:1945–8.</span> [<a href="/pubmed/12412800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12412800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.watanabe.2011.166">Watanabe A, Karasugi T, Sawai H, Naing BT, Ikegawa S, Orimo H, Shimada T. Prevalence of c.1559delT in ALPL, a common mutation resulting in the perinatal (lethal) form of hypophosphatasia&#x000a0;in Japanese and effects of the mutation on heterozygous carriers. <span><span class="ref-journal">J Hum Genet. </span>2011;<span class="ref-vol">56</span>:166–8.</span> [<a href="/pubmed/21179104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21179104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.watanabe.2014.93">Watanabe A, Satoh S, Fujita A, Naing BT, Orimo H, Shimada T. Perinatal hypophosphatasia caused by uniparental isodisomy. <span><span class="ref-journal">Bone. </span>2014;<span class="ref-vol">60</span>:93–7.</span> [<a href="/pubmed/24334170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24334170</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.wei.2010.1017">Wei KW, Xuan K, Liu YL, Fang J, Ji K, Wang X, Jin Y, Watanabe S, Watanabe K, Ojihara T. Clinical, pathological and genetic evaluations of Chinese patients with autosomal-dominant hypophosphatasia. <span><span class="ref-journal">Arch Oral Biol. </span>2010;<span class="ref-vol">55</span>:1017–23.</span> [<a href="/pubmed/20828673" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20828673</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.wenkert.2011.2389">Wenkert D, McAlister WH, Coburn SP, Zerega JA, Ryan LM, Ericson KL, Hersh JH, Mumm S, Whyte MP. Hypophosphatasia: nonlethal disease despite skeletal presentation in utero (17 new cases and literature review). <span><span class="ref-journal">J Bone Miner Res. </span>2011;<span class="ref-vol">26</span>:2389–98.</span> [<a href="/pubmed/21713987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21713987</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.whyte.2009.1132">Whyte MP. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. <span><span class="ref-journal">J Bone Miner Res. </span>2009;<span class="ref-vol">24</span>:1132–4.</span> [<a href="/pubmed/19113923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19113923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.whyte.1994.439">Whyte MP. Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. <span><span class="ref-journal">Endocr Rev. </span>1994;<span class="ref-vol">15</span>:439–61.</span> [<a href="/pubmed/7988481" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7988481</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.whyte.2012.904">Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, Van Sickle BJ, Simmons JH, Edgar TS, Bauer ML, Hamdan MA, Bishop N, Lutz RE, McGinn M, Craig S, Moore JN, Taylor JW, Cleveland RH, Cranley WR, Lim R, Thacher TD, Mayhew JE, Downs M, Mill&#x000e1;n JL, Skrinar AM, Crine P, Landy H. Enzyme-replacement therapy in life-threatening hypophosphatasia. <span><span class="ref-journal">N Engl J Med. </span>2012;<span class="ref-vol">366</span>:904–913.</span> [<a href="/pubmed/22397652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22397652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.whyte.2003.624">Whyte MP, Kurtzberg J, McAlister WH, Mumm S, Podgornik MN, Coburn SP, Ryan LM, Miller CR, Gottesman GS, Smith AK, Douville J, Waters-Pick B, Armstrong RD, Martin PL. Marrow cell transplantation for infantile hypophosphatasia. <span><span class="ref-journal">J Bone Miner Res. </span>2003;<span class="ref-vol">18</span>:624–36.</span> [<a href="/pubmed/12674323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12674323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.whyte.2016.334">Whyte MP, Rockman-Greenberg C, Ozono K, Riese R, Moseley S, Melian A, Thompson DD, Bishop N, Hofmann C. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2016;<span class="ref-vol">101</span>:334–42.</span> [<a href="/pmc/articles/PMC4701846/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4701846</span></a>] [<a href="/pubmed/26529632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26529632</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.yang.2013.635">Yang H, Wang L, Geng J, Yu T, Yao RE, Shen Y, Yin L, Ying D, Huang R, Zhou Y, Chen H, Liu L, Mo X, Shen Y, Fu Q, Yu Y. Characterization of six missense mutations in the tissue-nonspecific alkaline phosphatase (TNSALP) gene in Chinese children with hypophosphatasia. <span><span class="ref-journal">Cell Physiol Biochem. </span>2013;<span class="ref-vol">32</span>:635–44.</span> [<a href="/pubmed/24022022" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24022022</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.zhang.2012.21">Zhang H, Ke YH, Wang C, Yue H, Hu WW, Gu JM, Zhang ZL. Identification of the mutations in the tissue-nonspecific alkaline phosphatase gene in two Chinese families with hypophosphatasia. <span><span class="ref-journal">Arch Med Res. </span>2012;<span class="ref-vol">43</span>:21–30.</span> [<a href="/pubmed/22300680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22300680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hops.REF.zurutuza.1999.1039">Zurutuza L, Muller F, Gibrat JF, Taillandier A, Simon-Bouy B, Serre JL, Mornet E. Correlations of genotype and phenotype in hypophosphatasia. <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:1039–46.</span> [<a href="/pubmed/10332035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10332035</span></a>]</div></li></ul></div><div id="hops.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hops.REF.whyte">Whyte MP. Hypophosphatasia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <em>The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</em> Chap 207. New York, NY: McGraw-Hill.</div></li></ul></div></div><div id="hops.Chapter_Notes"><h2 id="_hops_Chapter_Notes_">Chapter Notes</h2><div id="hops.Author_Notes"><h3>Author Notes</h3><ul><li class="half_rhythm"><div><a href="http://www.sesep.uvsq.fr/03_hypo_mutations.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>ALPL</i> Mutation Database</a></div></li><li class="half_rhythm"><div><a href="http://www.clinchem.org/content/58/5/854/suppl/DC1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Pediatric Laboratory Reference Intervals for alkaline phosphatase</a> [<a class="bk_pop" href="#hops.REF.colantonio.2012.854">Colantonio et al 2012</a>] (see Supplemental Table 2)</div></li></ul></div><div id="hops.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>4 February 2016 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 November 2011 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>ALPL</i> available clinically</div></li><li class="half_rhythm"><div>5 August 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 November 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>18 December 2006 (men) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1150</span><span class="label">PMID: <a href="/pubmed/20301329" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301329</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hypo-mcc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/image/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1150&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1150/?report=reader">PubReader</a></li><li><a href="/books/NBK1150/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1150" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1150" style="display:none" title="Cite this Page"><div class="bk_tt">Mornet E, Nunes ME. Hypophosphatasia. 2007 Nov 20 [Updated 2016 Feb 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1150/pdf/Bookshelf_NBK1150.pdf">PDF version of this page</a> (785K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hops.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hops.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hops.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hops.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hops.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hops.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hops.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hops.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hops.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hops.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hops.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=249[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ALPL</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1483038" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1483038" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1483038" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1483038" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17916236" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypophosphatasia.</a><span class="source">[Orphanet J Rare Dis. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypophosphatasia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mornet E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2007 Oct 4; 2:40. Epub 2007 Oct 4.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301472" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL1A1/2</i> Osteogenesis Imperfecta</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">COL1A1/2</i> Osteogenesis Imperfecta<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Steiner RD, Basel D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28127875" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Molecular and clinical analysis of ALPL in a cohort of patients with suspicion of Hypophosphatasia.</a><span class="source">[Am J Med Genet A. 2017]</span><div class="brieflinkpop offscreen_noflow">Molecular and clinical analysis of ALPL in a cohort of patients with suspicion of Hypophosphatasia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tenorio J, Álvarez I, Riancho-Zarrabeitia L, Martos-Moreno GÁ, Mandrile G, de la Flor Crespo M, Sukchev M, Sherif M, Kramer I, Darnaude-Ortiz MT, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med Genet A. 2017 Mar; 173(3):601-610. Epub 2017 Jan 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301306" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CLCN7</i>-Related Osteopetrosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CLCN7</i>-Related Osteopetrosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sobacchi C, Villa A, Schulz A, Kornak U. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31482504" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.</a><span class="source">[Adv Exp Med Biol. 2019]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alkaline Phosphatase Replacement Therapy for Hypophosphatasia in Development and Practice.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bowden SA, Foster BL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Adv Exp Med Biol. 2019; 1148:279-322. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301329" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301329" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04124875f66d18aaf1879d">Hypophosphatasia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hypophosphatasia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:52:08-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C9E8DE040B1C10000000003030116&amp;ncbi_session=CE8C9E8DE0412471_0771SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1150%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1150&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1150/&amp;ncbi_pagename=Hypophosphatasia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C9E8DE0412471_0771SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>